Sustained Molecular Remissions Reported in Patients With Relapsed/Refractory CLL After CD19 CAR-T Infusion – Targeted Oncology
Targeted Oncology |
Sustained Molecular Remissions Reported in Patients With Relapsed/Refractory CLL After CD19 CAR–T Infusion
Targeted Oncology About 71% of patients (17 of 24) with chronic lymphocytic leukemia (CLL) exhibited an overall response (complete and/ or partial response) 4 weeks after receiving chimeric antigen receptor (CAR) T cell infusion therapy. The patients received … |
